{"prompt": "['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 47/80', 'lactate dehydrogenase, total serum bile acid, albumin, total proteins, triglycerides,', 'cholesterol (total, low density lipoprotein, and high density lipoprotein), creatine kinase,', 'and C-reactive protein.', '-', 'Urinalysis:', 'Dipstick: pH, glucose, proteins, blood, leucocytes, ketones.', 'Microscopic examination of the sediment (cylinders, erythrocytes, leucocytes) if', 'indicated.', '- Serology: hepatitis B surface antigen, hepatitis C virus antibody, and HIV-1 and HIV-2', 'antibodies (only at screening). Positive hepatitis and HIV results should be reported by', 'the investigator as required by local law.', '-', 'FSH test for females at screening to confirm menopause if applicable.', '-', 'Pregnancy test for females: serum beta human chorionic gonadotropin at screening, urine', 'pregnancy test on a monthly basis (only for WOCBP).', 'The clinical laboratory evaluations will be performed at visits specified in the Schedule of', 'Activities in Section 6.11 (see also Section 6.1, \"Timing of Assessments\"). Reference ranges', 'will be supplied by the central laboratory. Clinical laboratory values outside the normal range', 'will be flagged and clinical relevance will be assessed by the investigator. Only laboratory test', 'abnormalities judged as clinically significant by the principal investigator should be recorded', 'as AEs.', 'The details of blood and urine sample handling and shipment instructions will be provided in a', 'separate laboratory manual.', '6.6.3. Physical Examination', \"Physical examinations will be conducted by a physician, trained physician's assistant, or nurse\", 'practitioner (as acceptable according to local regulation) at visits specified in the Schedule of', 'Activities in Section 6.11. The person conducting the physical examination will document this', \"in the subject's medical records. Clinically significant abnormal findings should be recorded as\", 'AEs. Height and weight will only be recorded at screening.', '6.6.4. Vital Signs', 'Vital signs (SBP, DBP, heart rate, respiratory rate, and body temperature) will be recorded in a', 'standardized manner (i.e. after the subject has rested in a supine position for 5 minutes) at visits', 'specified in the Schedule of Activities in Section 6.11. Clinically significant abnormal values', 'should be recorded as AEs.', '6.6.5. 12-lead Electrocardiogram', 'At the time points specified in the Schedule of Activities (see Section 6.11) a 12-lead ECG will', 'be recorded and results will be sent for central reading. Triplicate ECGs will be performed', 'irrespective of IMP intake at Visit 1 (screening), within 30 minutes before IMP intake and', 'between 2 to 3 hours after IMP intake at Visit 2 (baseline) and Visit 3. A single ECG will be', 'performed within 30 minutes before IMP intake at Visits 7 and 9, and irrespective of IMP intake', 'at ED (if applicable) and Follow-up Visit 1. The ECG must be taken after subjects rested for at', 'least 5 minutes in the supine position. In case an indwelling catheter is used, ECGs may be', 'recorded after blood sampling, provided that there is at least 30 minutes between catheter', 'insertion and the ECG recording. When catheter insertion would fail, the 12-lead ECG needs to', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 48/80', 'be taken before the venipuncture and at least 30 minutes after the failed attempt. Triplicate', 'ECGs will be performed preferably within a time span of 6 minutes, with an approximate 2-', 'minute interval between ECGs. Parameters to be recorded include the following: heart rate, PR', 'interval, QRS interval, uncorrected QT interval, morphology, and rhythm analysis. QTcF will', 'be considered as normal if <450 ms, while a prolongation of QTcF to >500 ms or an increase', 'from baseline >60 ms will be considered a threshold of concern. Immediately after recording,', 'the ECG will be reviewed by the investigator on clinically significant abnormalities. This', \"immediate review during the visit needs to be documented in the subject's source. After receipt\", 'of the central report, also all flagged ECG abnormalities need to be assessed by the investigator', 'on clinical relevance. Clinically significant abnormal values should be recorded as AEs.', '_', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']\n\n###\n\n", "completion": "END"}